Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Cambridge Antibody Technology.
Recruitment status was  Recruiting
Study NCT00515892   Information provided by Cambridge Antibody Technology

First Received on August 10, 2007.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Non-Hodgkin's Lymphoma
NHL
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Immunotoxin therapy
CAT-8015 Immunotoxin
Biological therapy
Antibody Therapy
Monoclonal Antibody Therapy
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Immunotoxins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Cambridge Antibody Technology


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services